Compare Docusign Inc (DOCU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Twist Bioscience Corp — how do they compare? Docusign Inc trades at $71 (market cap $12.88B), while Twist Bioscience Corp trades at $158.01 (market cap $10.32B). The key difference: Docusign Inc is the larger of the two by market cap, and Docusign Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Twist Bioscience Corp for 27 Days on average.
| DOCU | TWST | |
|---|---|---|
Market Cap | $12.88B | $10.32B |
Volume | 2,591,969 | 5,894,998 |
Sector | Technology | Health |
52-Week High | $73.14 | $205.00 |
52-Week Low | $41.75 | $25.45 |
Typical Hold Time | 71 Days | 27 Days |
Enterprise Value | $12.28B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.43, up 4.71% with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows robust revenue growth reaching $2.98B in 2025 with improving profit margins, though valuation ratios remain elevated. Recent news highlights AI integration in contract processing and leadership recognition in workflow software.
Outlook remains positive with projected revenue growth to $3.4B in 2026, supported by AI adoption and operating leverage. Risks include insider selling, competitive pressures, and high valuation multiples. Analyst consensus is cautious with 64% hold ratings, but technical strength and fundamental improvements suggest potential for continued upside if execution persists.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
